APOPTOTIC EFFECT OF MAJMUIY RAXMONIY AND ASKALTSIY COMPLEXES IN GLIOBLASTOMA CELLS
Article Sidebar
Main Article Content
Abstract
In this study, the effect of Majmuiy Raxmoniy and Askaltsiy complexes on the apoptosis process in glioblastoma cells was evaluated using the Annexin V–FITC/PI flow cytometry method. The results demonstrated that these complexes activated apoptosis in tumor cells in a dose-dependent manner. Minimal apoptotic activity was observed in the control group, whereas the apoptotic index increased sharply in cells treated with Doxorubicin. Treatment with Majmuiy Raxmoniy (0.01%) significantly enhanced the level of apoptosis, while Askaltsiy (0.01%) exhibited the highest apoptotic response. The proportion of necrotic cells was <1%, indicating that the complexes possess a natural apoptogenic effect, inducing programmed cell death via the mitochondrial pathway rather than through toxicity. These results provide a scientific basis for the antitumor, cytoprotective, and immunoregulatory potential of Majmuiy Raxmoniy and Askaltsiy complexes in glioblastoma therapy.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1.Louis DN, Perry A, Reifenberger G, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 2021;142(3):341–358.
2.Fulda S, Debatin KM. Apoptosis pathways in neuroblastoma therapy. Cancer Letters. 2019;469:77–84.
3.Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–257.
4.Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646–674.
5.Elmore S. Apoptosis: A review of programmed cell death. Toxicologic Pathology. 2007;35(4):495–516.
6.Poon IKH, Lucas CD, Rossi AG, Ravichandran KS. Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol. 2014;14(3):166–180.
7.Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Reports. 2014;6:13.
8.Lotfi R, Herzog GI, Baumann I. Danger signals in glioblastoma: DAMPs and extracellular ATP promote immunosuppression and tumor progression. Front Immunol. 2020;11:595034.
9.Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: The beginning of the end of cancer? BMC Med. 2016;14(1):73.
10.Xu D, Lin TH, Li S. Natural flavonoids as apoptosis inducers in glioblastoma cells: molecular mechanisms and therapeutic potential. Front Pharmacol. 2022;13:875421.
11.Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: An overview. Sci World J. 2013;2013:162750.
12.Su J, Ye Y. Natural compounds in glioblastoma therapy: Modulation of apoptosis and immune response. Phytomedicine. 2021;91:153692.
13.Zhao H, Jiang J, Fan X, Hu W. Interleukin-mediated immune regulation in glioblastoma: From mechanisms to therapies. Front Immunol. 2020;11:594659.
14.Liu Y, Zeng B, Zhang Z, et al. Targeting NF-κB and STAT3 signaling pathways in glioblastoma: role of phytochemicals. Front Oncol. 2021;11:642349.
15.Al-Snafi AE. Therapeutic properties of natural plant-derived bioactive compounds with anti-glioma effects. J Pharm Res Int. 2020;32(9):39–55.